Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Hepion Pharmaceuticals, Inc. HEPA
$6.66
-$1.3 (-19.53%)
На 18:01, 12 мая 2023
-47.45%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
656618906.00000000
-
week52high
9.50
-
week52low
0.26
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.63391000
-
EPS
-0.58000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 апр 2023 г. в 16:00
Описание компании
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 28 февр 2022 г. | |
| Brookline Capital | Buy | 22 ноя 2019 г. | |
| Maxim Group | Hold | Buy | 20 мар 2019 г. |
| Maxim Group | Buy | Hold | 10 июл 2018 г. |
| Maxim Group | Buy | Buy | 06 мая 2016 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wijngaard Peter | A | 260000 | 200000 | 18 мая 2021 г. |
| JACOB GARY S | A | 342785 | 250000 | 18 мая 2021 г. |
| Foster Robert T | A | 2501879 | 1900000 | 18 мая 2021 г. |
| Cavan John T | A | 1581060 | 1200000 | 18 мая 2021 г. |
| BRANCACCIO JOHN P | A | 291332 | 200000 | 18 мая 2021 г. |
| Block Timothy M. | A | 291276 | 200000 | 18 мая 2021 г. |
| ADAMS THOMAS PHD | A | 291050 | 200000 | 18 мая 2021 г. |
| Lippa Arnold | A | 291110 | 200000 | 18 мая 2021 г. |
| Cavan John T | A | 14800 | 10000 | 18 февр 2021 г. |
| Foster Robert T | A | 45259 | 20000 | 18 февр 2021 г. |
Новостная лента
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
GlobeNewsWire
17 апр 2023 г. в 16:15
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Officer, Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting, which is being held April 15-19, 2023, in Orlando, Florida.
10 Best-Performing Penny Stocks in the Health Care Sector
24/7 Wall Street
03 апр 2023 г. в 22:49
The healthcare sector has more high return generating companies than many other sectors.
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023
GlobeNewsWire
05 янв 2023 г. в 16:15
EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the NASH-TAG 2023 Conference, which is being held January 5-7, 2022, in Park City, Utah.
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
GlobeNewsWire
15 июн 2022 г. в 08:00
- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –